Skip to main content

Mendlein John's Form 4 filing

Fate Therapeutics Inc (FATE) · filed Mar 11, 2022

Accession no.
0001209191-22-018188
Filed
Mar 11, 2022
Trade date
Mar 10, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.11M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mendlein JohnCIK 0001238362Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 10, 2022Common StockMOption exerciseAcquired+31,562$1.63+$51,446.06191,017Direct
Mar 10, 2022Common StockSSaleDisposed−19,493$34.73−$676,991.89171,524Direct
Mar 10, 2022Common StockSSaleDisposed−12,069$35.48−$428,208.12159,455Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2022Common StockMOption exerciseDisposed−31,562$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)